USPTO 2015–2025 USPTO PatentsView US Corporation

Biovision Technologies, LLC

USPTO PatentsView assignee record - 11 granted patents across 2 technology areas, recorded in grant years 2016–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

RSS updates for this company

The verdict

According to USPTO PatentsView, Biovision ranks #23,989 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 2 technology areas.

#23,989
of 49,997 US assignees by volume
11th percentile
by Innovation Score (23.0/100)
15.6
avg claims per patent
-78%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23989 · US Corporation #23,989 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 11 grants
  • MID-PACK #23,989/49,997
  • PHOTO-FINISH Bioprojet
  • CPC-NARROW A61B · 2 areas
  • INNOV-THIN 23.0/100
  • CLAIMS-RICH 15.6 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -78% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Bioprojet (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Biovision’s 23.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Biovision

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Biovision's Innovation Score is 23.0/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Biovision?

Each dot is one of Biovision’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Biovision’s own 15.6 claims/patent is at or below the 16.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Biovision vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 10.910.91111.1 10152025 Granted patents (volume) Avg claims / patent Bioprojet - 11, 12BioprojetBiosafe SA - 11, 17.18BiosafeBiothera Inc. - 11, 19.36BiotheraBiothread LLC - 11, 22.73BiothreadBlue Solutions Canada Inc. - 11, 14.73Blue Solutions Ca…Blue Tomato, LLC - 11, 16.64Blue TomatoBluedot Innovation PTY Ltd. - 11, 16.91Bluedot Innovatio…BNL Eurolens - 11, 16.55BNL EurolensBiovision Technologies, LLC - 11, 15.64Biovision
Biovision vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Biovision's grants concentrate

Biovision Technologies, LLC is a focused PatentsView assignee: 2 CPC subclasses with 90.9% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2016 (4 grants) versus a trough of 1 in 2019. By volume, Biovision sits between Bioprojet and BNL Eurolens.

Who files at Biovision's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Biovision holds 11 patents at rank #23,968, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Biovision

By rank, the assignees closest to #23,968 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Biovision's primary technology class.

Biovision's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

23 11th percentile higher than 11% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 201620172018201920202021 1
USPTO utility patent grants by year · 2016–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Biovision Technologies, LLC patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 4 36.4%
2017 2 18.2%
2018 2 18.2%
2019 1 9.1%
2020 1 9.1%
2021 1 9.1%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Biovision Technologies, LLC's patent record in context - here's where to go next.

  • Biovision Technologies, LLC's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 90.9% of its portfolio - see every assignee active in that class. Explore A61B
  • Ranked #23,989 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Biovision Technologies, LLC against Bioprojet, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 23.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.